Key result
Angiotensin II negatively regulates MAPKs in cultured rat neonatal cardiac myocytes through AT1 receptors by increasing MKP-1 mRNA levels and through AT2 receptors by unknown mechanisms.
Angiotensin II negatively regulates MAPKs in cardiac myocytes via two distinct mechanisms involving AT1 and AT2 receptors, providing insight into the molecular pathways of cardiac hypertrophy.
Does not support clinical practice changes; hypothesis-generating for Ang II-MAPK signaling in hypertrophy models.
Increasing evidence has suggested that mitogen-activated protein kinases (MAPKs) play important roles in the development of cardiac hypertrophy. We and others have reported that the activity of MAPKs is tightly regulated by angiotensin II (Ang II) in cardiac myocytes. In the present study, we determined the molecular mechanism of Ang II-induced inactivation of MAPKs in rat neonatal cardiac myocytes. Ang II increased MAPK phosphatase 1 (MKP-1) gene expressions within 10 min. Levels of MKP-1 transcripts peaked at 30 min and gradually decreased thereafter. The increase in MKP-1 mRNA levels was Ang II-concentration dependent. An Ang II type 1 receptor (AT1)-specific antagonist, CV-11974, completely suppressed the Ang II-induced increase in MKP-1 gene expression, while a type 2 receptor (AT2)-specific antagonist, PD-123319, had no significant effects. Induction of MKP-1 gene expressions by Ang II was inhibited by pretreatment with an intracellular Ca2+ chelator, BAPTA-AM, or with the protein kinase C inhibitors, H-7 and Calphostin C. Phorbol ester and Ca2+ ionophore both significantly increased MKP-1 mRNA levels and showed synergistic action. Overexpression of MKP-1 cDNA blocked the Ang II-induced increase in expressions of immediate early response genes. In addition, Ang II-induced MAPK activation was significantly inhibited by pretreatment with CV-11974, but significantly enhanced by pretreatment with PD-123319. Addition of the AT2 agonist, CGP42112A, reduced basal MAPK activities, and pretreatment with PD-123319 abolished MAPK inactivation by CGP42112A. In conclusion, these observations suggest that Ang II negatively regulates MAPKs through AT1 receptors by increasing MKP-1 mRNA levels and through AT2 receptors by unknown mechanisms.
No takes yet. Share an insight, caveat, or question.
Hiroi et al. (2001) studied Cardiac hypertrophy (in vitro model). Angiotensin II was evaluated on MAPK phosphatase 1 (MKP-1) gene expression and MAPK activation. Angiotensin II negatively regulates MAPKs in cultured rat neonatal cardiac myocytes through AT1 receptors by increasing MKP-1 mRNA levels and through AT2 receptors by unknown mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: